Publications

PUBLICATIONS FROM WORK DONE AT THE SCLERODERMA CENTER:

Published Manuscripts

  1. Sullivan KM, Wigley FM, Denton CP, van Laar JM, Furst DE. Haemopoietic stem-cell transplantation for systemic sclerosis. Lancet. 2012 Jan 21;379(9812):219; author reply 219-20.
  2. Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F.  Efficacy of Rho-Kinase inhibitor fasudil in secondary Raynaud’s phenomenon. Arthritis Care Res (Hoboken). 2012 Jan 24. [Epub ahead of print]
  3. Mittoo S, Wigley FM, Wise RA, Woods A, Xiao H, Hummers LK. Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease.  Open Rheumatol J. 2011 Jan 13;5:1-6.
  4. DeZern AE, Petri M, Drachman DB, Kerr D, Hammond ER, Kowalski J, Tsai HL, Loeb DM, Anhalt G, Wigley F, Jones RJ, Brodsky RA.  High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other auoimmune diseases.  Medicine (Baltimore).  2011 Mar;90(2):89-98.
  5. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, van Riel PL, van ‘t Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF, Spanish Scleroderma Group, Airo P, van Laar J, Herrick A, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, May Chee M, Madhok R, Shiels P, Westhovens R, Kreuter A, Kiener H, de Baere E, Witte T, Padykov L, Klareskog L, Beretta L, Scorza R, Lie BA, Hoffmann-Vold AM, Carreira P, Varga J, Hinchcliff M, Gregersen PK, Lee AT, Ying J, Han Y, Weng SF, Amos CI, Wigley FM, Hummers L, Nelson JL, Agarwal SK, Assassi S, Gourh P, Tan FK, Koeleman BP, Arnett FC, Martin J, Mayes MD.  Corrigendum: Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2011 May;42(5):426-9.
  6. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011 Jun;70(6):1104-7
  7. Knafo R, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD.  The association of body image dissatisfaction and pain with reduced sexual function in women with systemic sclerosis.  Rheumatology (Oxford). 2011 Jun;50(6):1125-30.
  8. Walker KM, Pope J, Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group.  Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.  J Rheumatol.  2011 Jul;38(7):1326-8.8.Manno RL, Wigley FM, Gelber AC, Hummers LK. Late-Age Onset Systemic Sclerosis. J Rheumatol. 2011 Jul;38(7):1317-25.
  9. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Lechtzin N, Chami H, Girgis RE, Hassoun PM. Outcomes of hospitalization for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011 Aug;38(2):359-67.
  10. Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, Zaiman A, Sitbon O, Simonneau G, Humbert M, Hassoun PM.  Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease:  impact of pulmonary arterial hypertension therapies.  Arthritis Rheum. 2011 Aug;63(8):2456-64.
  11. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, Diaz-Gallo LM, Broen JC, Vonk MC, Simeon CP, Alizadeh BZ, Coenen MJ, Voskuyl AE, Schuerwegh AJ, van Riel PL, Vanthuyne M, van ‘t Slot R, Italiaander A, Ophoff RA, Hunzelmann N, Fonollosa V, Ortego-Centeno N, González-Gay MA, García-Hernández FJ, González-Escribano MF, Airo P, van Laar J, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels PG, Westhovens R, Kreuter A, de Baere E, Witte T, Padyukov L, Nordin A, Scorza R, Lunardi C, Lie BA, Hoffmann-Vold AM, Palm O, García de la Peña P, Carreira P; Spanish Scleroderma Group, Varga J, Hinchcliff M, Lee AT, Gourh P, Amos CI, Wigley FM, Hummers LK, Nelson JL, Riemekasten G, Herrick A, Beretta L, Fonseca C, Denton CP, Gregersen PK, Agarwal S, Assassi S, Tan FK, Arnett FC, Radstake TR, Mayes MD, Martin J.  Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.  PLoS Genet.  2011 Aug;7(8): doi: 10:1371.
  12. Grader-Beck T, Boin F, von Gunten S, Smith D, Rosen A, Bochner BS. Antibodies recognizing sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease.  Ann Rheum Dis. 2011 Dec;70(12):2218-24.
  13. Jewett LR, Hudson M, Haythornthwaite JA, Heinberg L, Wigley FM, Baron M, Thombs BD; Canadian Scleroderma Research Group (CSRG) Investigators.  Development and validation of the brief-satisfaction with appearance scale (brief-SWAP) for systemic sclerosis (SSc).  Arthritis Care Res (Hoboken). 2010 Dec;62(12):1779-86.
  14. Boueiz A, Mathai SC, Hummers LK, Hassoun PM.  Cardiac complications of systemic sclerosis: recent progress in diagnosis.  Curr Opin Rheumatol.  2010 Nov;22(6):696-703.
  15. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Muller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyle M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumanovics G, Coleiro B, Feieri E, Szucs G, Von Muhlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kotter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.  Ann Rheum Dis. 2010 Oct;69(10):1809-15.
  16. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.  Arthritis Rheum. 2010 Sep;62(9):2787-95.
  17. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR Investigators.  Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.  J Rheumatol.  2010 Jul;37(7):1488-501.
  18. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Champion HC, Lechtzin N, Wigley FM, Girgis RE, Hassoun PM.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2010 Jul 15;182(2):252-60.
  19. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, van Riel PL, van ‘t Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, Gonzalez,Gay MA, Gonzalez-Escribano MF; Spanish Scleroderma Group.  Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus.  Nat Genet. 2010 May;42(5):426-9.
  20. DeZern AE, Petri M, Drachman DB, Kerr D, Hammond ER, Kowalski J, Tsai HL, Loeb DM, Anhalt G, Wigley F, Jones RJ. Brodsky RA. High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.  Medicine (Baltimore). 2011 Mar;90(2):89-98.
  21. Atamas SP, Luzina IG, Ingels J, Choi J, Wong WK, Furst DE, Clements PJ; Investigators of the Oral Collagen Trial in Scleroderma, Postlethwaite AE.  Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma).  Clin Exp Immunol. 2010 Sep;161(3):426-35.
  22. Le EN, Freischlag JA, Christo PJ, Chhabra A, Wigley FM.  Thoracic outlet syndrome secondary to localized scleroderma treated with botulinum toxin injection.  Arthritis Care Res (Hoboken). 2010 Mar;62(3):430-3.
  23. Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakurl CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Kenne DR, Sakai LY, Dietz HC. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med.  2010 Mar 17;2(23):23ra20.
  24. Hummers LK. The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep. 2010 Feb;12(1):34-9.
  25. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension.  J Rheumatol. 2010 Jan;37(1):98-104.
  26. Mathai SC, Bueso M, Hummers LK, Boyce D, Lechtzin N, Le Pavec J, Campo A, Champion HC, Housten T, Forfia PR, Zaiman AL, Wigley FM, Girgis RE, Hassoun PM. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J.  2010 Jan;35(1):95-104.
  27. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, Riemekasten G, Cozzi F, Beretta L, Derk CT, Komosi A, Farge D, Balbir A, riccieri V, Distler O, Chiala A, del papa N, Simic Pasalic K, Ghio M, Stamenkovic B, Rednic S, Host N, Pellerito R, Zegers E, Kahan A, Walker UA, Matucci-Cerinic and EUSTAR Research Group. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients. Ann Rheum Dis. 2010 Jan;69(1):218-21.
  28. Girgis RE, Mathai SC, Wigley FM, Hassoun PM. Survival in systemic sclerosis-related pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009 Dec 15;180(12):1280; author reply 1280-1.
  29. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct;36(10):2244-9.
  30. Knafo R, Thombs BD, Jewett L, Hudson M, Wigley F, Haythornthwaite JA. (Not) talking about sex: a systematic comparison of secual impairment in women with systemic sclerosis and other chronic disease samples. Rheumatology (Oxford). 2009 Oct;48(10):1300-3.
  31. Sherber NS, Boin F, Hummers LK, Wigley FM. The “tank top sign”: a unique pattern of skin fibrosis seen in pansclerotic morphea. Ann Rheum Dis. 2009 Sep;68(9):1511-2.
  32. Song P, Gocke C, Wigley FM, Boin F. Resolution of pansclerotic morphea after treatment with antithymocyte globulin. Nat Rev Rheumatol. 2009 Sep;5(9):513-6.
  33. Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Casciola-Rosen L. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum. 2009 Aug;60(8):2480-9.
  34. Boin F, Wigley F. Connective tissue diseases: Immunosuppressive therapy in SSc: What is the taret? Nat Rev Rheumatol. 2009 Jul;5(7):357-8
  35. Wigley FM. Vascular Disease in Scleroderma. Clin Rev Allergy Immunol. 2009 June; 36(2-3):150-75.
  36. Sherber NS, Wigley FM, Paget SA.  Diffuse fasciitis with eosinophilia developing after local irradiation for breast cancer.  Clin Rheumatol.  2009 Jun;28(6):729-32.
  37. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst dE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Garay Toth B, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May;68(5):620-8.
  38. Avouac J, Kowal-Bielecka O, Landewe RB, Chwiesko S, Miniati I, Czirjak L, Clements PJ, Denton CP, Farge D, Fligelstone K, Foeldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takahara K, Garay Toth B, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M. EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. 2009 May;68:629-34.
  39. Luzina IG, Todd NW, Nacu N, Lockatell V, Choi J, Hummers LK, Atamas SP. Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes. Arthritis Rheum. 2009 May;60(5):1530-9.
  40. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium.  Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement:  a randomized, double-blind, placebo-controlled trial.  Arthritis Rheum.  2009 Apr;60(4):1102-11.
  41. Loizos N, LaRiccia L, Weiner J, Griffin H, Boin F, Hummers LK, Wigley FM, Kussie P. Lack of detection of agonist activity by antibodies to Platelet-derived growth factor (PDGF) receptor alpha in a subset of normal and systemic sclerosis (scleroderma). Arthritis Rheum.  2009 Apr;60(4):1145-51.
  42. Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the Regulators of Angiogenesis in Patients with Scleroderma. J Rheumatol. 2009 March; 36(3):576-82.
  43. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases:  impact of interstititial lung disease.  Arthritis Rheum.  2009 Feb;60(2):569-77.
  44. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Colier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM.  MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon:  A randomized, controlled trial.  Arthritis Rheum.  2009 Feb 26; 60(3):870-7.
  45. Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford). 2009 Feb; 48(2):165-9.
  46. Hummers LK. The importance of recognizing scleroderma-type disorders in clinical practice. Nat Clin Prac Rheum. 2008 Dec; 4(12):638-40.
  47. Hummers LK. Biomarkers of vascular disease in scleroderma. Rheumatology (Oxford). 2008 Oct;47 Suppl 5; v21-2.
  48. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP; Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008 Aug; 134(2):358-67.
  49. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE for the other coauthors of the EPOSS-OMERACT group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75.
  50. Wung PK, Pipeling MR, Wigley FM. “Still” Ill? Am J Med. 2008 Jun; 121(6):491-3.
  51. Tehlirian CV, Hummers LK, White B, Brodsky RA, Wigley FM. High dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis. 2008 Jun; 67(6): 775-81
  52. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Splera R, Steen V, Warrington K, White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008 May 31; 58(6):1810-22.
  53. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, Houston-Harris T, Cheadle C, Gao L, Hummers LK, Champion HC, Garcia JG, Wigley FM, Tuder RM, Barnes KC, Hassoun PM. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res. 2008 Apr;151 (4) :197-207.
  54. Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum, 2008 Apr; 58(4):1165-74.
  55. Shah AA, Wigley FM. Often forgotten manifestations of systemic sclerosis. Rheum Dis Clin North Am. 2008 Feb;34 (1) : 221-38; ix. Review.
  56. Wigley FM. Systemic sclerosis (scleroderma) is unique among our rheumatic diseases. Preface. Rheum Dis Clin North Am. 2008 Feb;34 (1) : xi-xiii.
  57. Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am. 2008 Feb;34(1):199-220.
  58. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine. 2008 Jan;87(1):10-20.
  59. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP, The Scleroderma Lupus Study Research Group. Brochoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan;177(1) : 91-8.
  60. Soong TK, Barouch LA, Champion HC, Wigley FM, Halushka MK. New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy – a report of 2 cases. Hum Pathol. 2007 Dec; 38(12):1858-63.
  61. Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L. Persistence of an abnormal BAL after cyclophosphamide treatment in scleroderma interstitial lung disease. Arthritis Rheum. 2007 Dec; 56(12):4195-202.
  62. Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: evidence-based review. Curr Opin Rheumatol. 2007 Nov;19(6) : 611-8. Review.
  63. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
  64. Mulligan-Kehoe MJ, Drinane MC, Mollmark J, Casciola-Rosen L, Hummers LK, Hall A, Rosen A, Wigley FM, Simons M. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum. 2007 Oct; 56(10):3448-58.
  65. Lam GK, Hummers LK, Woods A, Wigley F. Efficacy and safety of Etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol. 2007 Jul; 34(7):1636-7.
  66. Walker UA, Tyndall A, Czirjak L, Denton CP, Bancel DF, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M; EULAR Scleroderma Trials. Clinical risk assessment of organ manifestations in systemic sclerosis – a report from the EULAR Scleroderma Trials and Research (EUSTAR) group data base. Ann Rheum Dis. 2007 Jun; 66(6):754-63.
  67. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
  68. Boin F, Rosen A. Autoimmunity in systemic sclerosis: current concepts. Curr Rheumatol Rep. 2007 May;9(2):165-72.
  69. Heinberg LJ, Kudel I, White B, Kwan A, medley K, Wigley F. Assessing body image in patients with systemic sclerosis (scleroderma): validation of the adapted Satisfaction with Appearance Scale. Body Image. 2007 Mar;4(1):79-86.
  70. Schachna L, Medsger TA, Dauber JH, Wigley FM, Braunstein NA, White B, Steen VD, Conte JV, Yang SC, McCurry KR, Borja MC, Plaskon DE, Orens JB, Gelber AC. Lung transplantation in scleroderma compared to idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006 Dec; 54(12):3954-61.
  71. Roberts CGP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-controlled study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). GUT 2006 Dec; 55(12):1697-703.
  72. Sherber NS, Wigley FM, Anhalt GJ. Bullous pemphigoid in a patient with systemic sclerosis (scleroderma). J Rheum. 2006 Oct; 33(10:2098.
  73. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FM, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andres B, Abeles M, Clements PJ. Minimally important difference in diffuse systemic sclerosis: results from the D-Penicillamine Study. Ann Rheum Dis 2006 Oct; 65(10):1325-9.
  74. Edwards RR, Goble L, Kwan A, Kudel I, McGuire L, Heinberg L, Wigley FM, Haythornthwaite J. Catastrophizing, pain, and social adjustment in scleroderma: relationships with educational level. Clin J Pain. 2006 Sep; 22(7):639-46.
  75. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wigley FM, Hassoun PM. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006 Sep; 54(9):3043-50.
  76. Kamen DL, Wigley FM, Brown AN. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma—a different kind of renal crisis. J Rheumatol. 2006 Sep; 33(9):1886-8.
  77. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley FM, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly K, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, for the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 Jun; 354(25)2655-66.
  78. Hummers LK. Microvascular Damage in Scleroderma and the Use of Biomarkers to Detect it and Monitor Activity. Curr Rheumatol Rep. 2006 Apr; 8(2):131-7.
  79. Boin F, Sciubba JJ, Stone JH. Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distress. Arthritis Rheum 2006; 55:167-70.
  80. Cope KA, Solga SF, Hummers LK, Wigley FM, Diehl AM, Risby TH. Abnormal exhaled ethane concentrations in scleroderma. Biomarkers 2006;11(1):70-84.
  81. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33(2):269-74.
  82. Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, Rosen A, Casciola-Rosen LA. Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis 2006;65(8):1028-32.
  83. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. Reply. Arthritis Rheum 2006;54(1):380-1.
  84. Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol. 2005 Nov;17(6):752-60.
  85. Boin F, Wigley FM, Schneck JP, Oelke M, Rosen A. Evaluation of topoisomerase-1-specific CD8+ T-Cell response in systemic sclerosis. Ann N Y Acad Sci 2005;1062:137-45.
  86. Liu X, Zhu S, Wang T, Hummers L, Wigley FM, Goldschmidt-Clermont PJ, Dong C. Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med 2005;2(12):e354.
  87. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005;24(10):1626-31.
  88. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52(7):2125-32.
  89. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG,Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM,Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life,functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum.2005;52(2):592-600.
  90. Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley FM, Weisman MD, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Wong WK. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 2004;33(4):249-63.
  91. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J, Orlandi C, Czerwiec FS. Efficacy and tolerability of a selective alpha (2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004;50(12):3994-4001.

Book Chapters, Review Articles

  1. Shah AA.  Neglected Manifestations of Systemic Sclerosis. Scleroderma: From Pathogenesis to          Comprehensive Management. In press.
  2. Wung PK, Wigley FM. Systemic Sclerosis and Raynaud’s Phenomenon. In Weisman M, Weinblatt ME, Louie JS, & Van Vollenhoven RF (eds). Targeted Treatment for Rheumatic Diseases, 1st Edition. Elsevier, Philadelphia, PA. 2010:157-165.
  3. Manno R, Wigley F. Scleroderma in the Elderly. In Nakasato YR, Teasdale, Carnes (eds). Geriatric Rheumatology: A Comprehensive Textbook. The Humana Press Inc., Totowa, NJ, In press, 2010.
  4. Wigley FM. Preface. Rheum Dis Clin North Am. 2008 Feb; 34(1):xi-xiii.
  5. Shah AA, Wigley FM. Often forgotten manifestations of systemic sclerosis. Rheum Dis Clin North Am. 2008 Feb; 34(1):221-38.
  6. Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am. 2008 Feb; 34(1):199-220.
  7. Varga J, Wigley F. Systemic Sclerosis. In: Rich, Shearer, Fleisher, Schroeder, Weyand, Frew, editors. Clinical Immunology (3rd Ed). Elsevier Ltd., London, UK, 2008:813-823.
  8. Huston KK, Stone JH, Wigley FM. Digital ischemia and Raynaud’s phenomenon, In: Ball GV, Bridges Jr SL, editors. Vasculitis. Oxford University Press, New York, NY. 2008:209-223.
  9. Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: evidence-based review. Curr Opin Rheumatol. 2007 Nov; 19(6):611-8.
  10. Wigley FM. Clinical manifestations and diagnosis of the Raynaud phenomenon. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, 2007.
  11. Sherber NS, Wigley FM, Scher RK. Autoimmune disorders: nail signs and therapeutic approaches. Dermatol Therapy. 2007 Jan-Feb; 20(1):17-30.
  12. Boin F, Wigley FM. Systemic Sclerosis. In: Bartlett SJ, Bingham C, Marcic M, editors. Clinical Care in the Rheumatic Diseases (3rd Ed). ACR. Association of Rheumatology Health Professionals, Atlanta, GA. 2006:193-198.
  13. Sule S. Pediatric Rheumatic Diseases. In: Bartlett SJ, Bingham C, Marcic M, editors. Clinical Care in the Rheumatic Diseases (3rd Ed). ACR. Association of Rheumatology Health Professionals, Atlanta, GA.
  14. Hummers LK, Wigley FM. Scleroderma. In: Bartlett SJ, Bingham C, Marcic M, editors. Clinical Care in the Rheumatic Diseases (3rd Ed). ACR. Association of Rheumatology Health Professionals, Atlanta, GA.
  15. Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol 2005; 17(6):752-60.
  16. Grader-Beck T, Wigley FM. Raynaud’s phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 2005;31(3):465-81, vi. Review.
  17. Hummers Lk, Wigley FM. Scleroderma. In: Imboden J, hellmann D, Stone J (eds). Current Diagnosis & Treatment of Rheumatic Diseases, 2nd edition, New York: Lange Medical Books/McGraw-Hill, 2005.
  18. Wigley FM. Scleroderma (Systemic Sclerosis). In: Goldman L, Ausiello D, editors. Cecil Textbook of Medicine (22nd Ed). WB Saunders, Orlando, FL. 2004:1670-1677.

Abstracts (Presented at the American College of Rheumatology Annual Scientific Meeting, 2011)

  1.  Shah AA, Chung S-E, Wigley FM, Hummers LK.  The value of periodic echocardiography screening to detect pulmonary hypertension and predict mortality in scleroderma.
  2. Shah AA, Mayer S, Girgis R, Mudd J, Hummers LK, Wigley FM. Correlation between exercise echocardiography and right heart catherterization in scleroderma patients at risk for pulmonary hypertension.
  3. Hummers LK, Zimmerman S, Wigley FM, Carrino J, Schwetje E, Greth W, Shah AA. Measuring vascular burden in scleroderma and Raynaud phenomenon.
  4. Kushi J, Czuka ME, Hummers LK, Wigley FM, Hsu VM, Khanna D, Molitor JA, Steen VD.  Elevated pulmonary vascular resistance at rest is associated with exercise pulmonary arterial hypertension in systemic sclerosis patients without pulmonary hypertension hemodynamics at rest.
  5. Gelber AC, Manno RL, Woods A, Shah AA, Boin F, Hummers LK, Wigley FM.  Race and mortality risk in scleroderma.
  6. Paik J, Hummers LK, Wigley FM, Ghazarian SR, Daya NR, Shah AA, Imatinib Study Group.  Patient reported measures of skin activity associate with disability in diffuse scleroderma.
  7. Assassi S, Agarwal SK, Tan FK, Reveille JD, Zhou X, Arnett FC, Wigley FM, Hummers LK, Perry M, Simeon CP, Carriera P, Ortego-Centeno N, Gonzalez-Gay M, the Spanish Scleroderma Group.  Immunochip genotyping of 1,884 systemic sclerosis cases and 4,325 controls reveals novel associations.
  8. Martino J, Bossini-Castillo L, Gonzalez EB, Draeger HT, Ying J, Agarwal SK, Arnett FC, Wigley FM, Assassi S.  A functional IRF5 variant predicts prognosis in patients with systemic sclerosis.
  9. Paik J, Wigley FM, Hummers LK, Mammen AL.  Features of acute denervation in scleroderma myopathy.
  10. Seibold JR, Wigley FM, Schiopu E, Denton CD, Silver RM, Steen VD, Medsger TA, Mayes MD, Chatterjee S.  Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study.
  11. Seibold JR, Wigley FM, Schiopu E, Denton CD, Silver RM, Steen VD, Medsger TA, Mayes MD, Chatterjee S, Chung L, Csuka ME, Khanna D, Frech TM.  Systemic sclerosis fibrosing syndromes and Raynaud’s – Clinical aspects and therapeutics.
  12. Horn E, Bolster MB, Shapiro LS, Khanna D, Frech TM, Fields K, Derk CT, Hummers LK, Mayes MD, Steen VD, and PHARAOS Investigators.  Clinical and hemodynamic features of scleroderma patients with pulmonary venous hypertension versus pulmonary arterial hypertension.
  13. Fischer A, Molitor JA, Hummers LK, Hsu VM, Hinchcliff ME.  Severe interstitial lung disease within the PHAROS Registry:  Baseline characteristics and clinical features.
  14. Shah AA, Mayer S, Girgis, Mudd J, Hummers LK, Wigley FM.  Correlation between exercise echocardiography and right heart catheterization in scleroderma patients at risk for pulmonary hypertension.
  15. Shah AA, Chung S-E, Wigley FM, Hummers LK.  The value of periodic echocardiography screening to detect pulmonary hypertension and predict mortality in scleroderma.

Abstracts (Presented at the American College of Rheumatology Annual Scientific Meeting, 2010)

  1. Distler O, et al.  A multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis.
  2. Denton CP, et al. Comparative analysis of change in modified Rodnan Skin Score in patients with diffuse systemic sclerosis receiving Imatinib mesylate suggests similar disease course to matched patients receiving standard therapy.
  3. Gordon JK, et al.  Difficulty using World Health Organization criteria to categorize pulmonary hypertension in patients with systemic sclerosis (PHAROS).
  4. Manno RL, et al. Pulmonary hypertension by age of scleroderma onset and subtype.
  5. Le EN, et al.  Risk associated with African American race in relation in prevalence of cardinal organ system manifestations in scleroderma.
  6. Cottrell TR, et al.  The degree of skin involvement predicts distinct interstitial lung disease outcomes in systemic sclerosis.
  7. Shah AA, et al.  A pilot study to evaluate digital perfusion in scleroderma patients treated with oral Treprostinil.
  8. Schiopu E, et al. Open label trial of oral Treprostinil in patients with systemic sclerosis and history of digital ulcers:  multiple dose pharmacokinetics and tolerability.
  9. Jewett LR, et al.  Development and validation of the brief-satisfaction with appearance scale (Brief-SWAP) for measuring body image in systemic sclerosis (SSc).
  10.  Boin F, et al.  Circulating T cell polarization is associated with respiratory decline in scleroderma patients with active interstitial lung disease.
  11. Le E, et al. Long-term benefit of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.

Abstracts (Presented at the American College of Rheumatology Annual Scientific Meeting, 2009)

  1. Shah AA, Rosen A, Hummers LK, Wigley FM, Casciola-Rosen L.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.  Arthritis Rheum 60(10) (supplement):S166, 2009.
  2. Hummers LK, Simons M, Wigley FM, Mulligan-Kehoe MJ.  Circulating inhibitors of angiogenesis in scleroderma.  Arthritis Rheum 60(10) (supplement):S175, 2009.
  3. Gorlova O, Weng S-F, Ying J, Wigley FM, Hummers LK, Gregersen PK, Lee, AT, Amos C, Arnett FC, Assassi S, Gourh PR, Tan FK, Reveille JD, Nelson JL, McNearney TA, Fischbach M, Mayes M.  Genome-Wide association study of systemic sclerosis in a large US cohort of over 1,500 cases.  Arthritis Rheum 60(10) (supplement):S203-204, 2009.
  4. Jewett LR, Thombs BD, Hudson M, Heinberg L, Wigley FM, Haythornthwaite JA.  Measuring body image avoidance in patients with systemic sclerosis.  Arthritis Rheum 60(10) (supplement):S428, 2009.
  5. Shah AA, Wigley FM, Hummers LK.  Telangiectases in scleroderma:  a potential clinical marker of pulmonary arterial hypertension.  Arthritis Rheum 60(10) (supplement):S448, 2009.
  6. Manno RL, Wigley FM, Hummers LK.  Late-age onset scleroderma.  Arthritis Rheum 60(10) (supplement):S649-650, 2009.
  7. Valiyil R, Hummers LK, Wigley FM.  Myopathy independently predicts mortality in scleroderma patients.  Arthritis Rheum 60(10) (supplement):S651, 2009.
  8. Knafo R, Thombs BD, Wigley FM, Haythornthwaite JA.  Clinical correlates of sexual impairment in women with systemic sclerosis.  Arthritis Rheum 60(10) (supplement):S700, 2009.

Abstracts (Presented at the American College of Rheumatology Annual Scientific Meeting, 2008)

  1. Wung PK, Wigley FM, Hummers LK, Halushka MK, Rodriguez ER, Steenbergen C, Champion HC. Myocardial fibrosis and inflammation in scleroderma: histopathologic analysis. Arthritis Rheum 58(9) (supplement):S376-S377, 2008.
  2. Hsu V, Shapiro L, Fiorentino D, Rothfield N, Steen V, Martin R, Smith E, Sule S, Csuka ME, Mayes M, Kahaleh B, Gruber B, Simms R, Sweiss N, Dechow FJ, Gregory JK, Wigley FM. Phase III open-label study of topical nitroglycerin MQX-503, in the treatment and prevention of Raynaud’s phenomenon. Arthritis Rheum 58(9) (supplement):S820-S821, 2008.
  3. Rothfield N, Shapiro L, Fiorentino D, Chung L, Denton C, Herrick A, Baron M, Shanahan J, Hsu V, Belch J, Steen V, Scheja A, Martin R, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Sule S, Emery P, Wigley FM. Safety and tolerability of MQX-503, a novel investigational topical formulation of nitroglycerin for the treatment of Raynaud’s phenomenon. Arthritis Rheum 58(9) (supplement):S821, 2008.
  4. Herrick A, Denton C, Fiorentino D, Sule S, Rothfield N, Belch J, Shapiro L, Scheja A, Shanahan J, Steen V, Chung L, Emery P, Wigley F, Gregory J. Comparison of responders and non-responders to MQX-503, a novel investigational topical nitroglycerin formulation, in treatment of scleroderma-related and non-scleroderma-related Raynaud’s phenomenon. Arthritis Rheum 58(9) (supplement):S822, 2008.
  5. Loizos N, Weiner J, Griffin H, Boin F, Hummers LK, Wigley FM, Kussie P. Lack of evidence for agonist activity by auto-antibodies to platelet-derived growth factor (PDGF) receptor alpha in systemic sclerosis (scleroderma). Arthritis Rheum 58(9) (supplement):S927, 2008.
  6. Shah AA, Hummers LK, Champtiopn H, Steen V. Wigley FM. Exercise-induced diastolic dysfunction in scleroderma. Arthritis Rheum 58(9) (supplement):S946, 2008.
  7. Boin F, Johnson E, Rosen A, Wigley F, Casciola-Rosen L. Anti-beta2 glycoprotein I antibodies are independently associated with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 58(9) (supplement):S946-S947, 2008.
  8. Hinchcliff ME, Hsu V, Bolster M, Hummers L, Seibold J, Csuka ME, Chung L, Shapiro L, Derk C, Fischer A, Wigley F, Steen V. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): patients with pulmonary hypertension. Arthritis Rheum 58(9) (supplement):S948, 2008.

Abstracts (Presented at the American College of Rheumatology Annual Scientific Meeting, 2007)

  1. Sule SD, Hummers L, Shapiro L, Fiorentino D, Chung L, Baron M, Shanahan J, Hsu V, Rothfield N, Steen V, Martin R, Dugowson C, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Klaff L, Dechow FJ, Gregory J, Wigley FM. Safety and Tolerability of MQX-503, a Novel Investigational Topical Formulation of Nitroglycerin for the Treatment of Raynaud’s Phenomenon.
  2. Shah AA, Hummers LK, Schwartz P, Le B, Dellinger W, Stott D, Wise RA, Wigley FM. Ambulatory Raynaud’s Monitor: A Novel Measurement Devise to Assess Raynaud’s Phenomenon in an Ambulatory Setting.
  3. Chung L, Baron M, Collier D, Csuka ME, Fiorentino D, Gruber B, Hsu V, Kahaleh B, Martin R, Mayes M, Pope J, Rothfield N, Shanahan J, Shapiro L, Simms R, Smith E, Steen V, Sule S, Sweiss N, Matthews E, Gilbert A, Dechow FJ, Wigley FM. A Multi-Center Placebo-Controlled “In-Life” Study of MQX-503 in Patients with Raynaud’s Phenomenon.
  4. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin R, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Matthews E, Gilbert A, Dechow FJ, Gregory J, Wigley FM. MQX-503, a Novel Topical Nitroglycerin Formulation, Improves Severity of Raynaud’s phenomenon in a Heterogeneous Patient Population.
  5. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst D, Muller-Ladner U, Seibold J, Silver R, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, on behalf of EUSTAR centers. EULAR/EUSTAR Recommendations for the Treatment of Systemic Sclerosis (SSc).
  6. Denton CP, Fiorentino D, Herrick A, Sule S, Rothfield N, Belch J, Shapiro L, Scheja A, Shanahan J, Steen V, Emery P, Chung L, Gregory J, Batson E, Dooley T, Gilbert A, Dechow F, Wigley FM. A Multi-center Crossover Study of MQX-503, a Topical Formulation of Nitroglycerin, in Patients with Raynaud’s Phenomenon.

Abstracts (Presented at the American College of Rheumatology Annual Scientific Meeting, 2006)

  1. Christopher V. Tehlirian et al.: High dose cyclophosphamide without stem cell transplantation in systemic sclerosis.
  2. Shikha Mitto et al.: Long term pulmonary function and survival outcomes of scleroderma patients treated with cyclophosphamide (CYC) for active interstitial lung disease (ILD).
  3. Laura Hummers et al.: A multi-center, blinded, randomized, placebo-controlled study of MQX-503, a topical gel formulation of nitroglycerin, in patients with Raynaud’s phenomenon.
  4. Francesco Boin et al.: Diverging T cell polarization identifies distinct clinical phenotypes in systemic sclerosis.
  5. Sangeetta D. Sule et al.: Characterization of transforming growth factor (TGF)- β secretion from monocytes in systemic sclerosis.

Abstracts (Presented at the American College of Rheumatology Annual Scientific Meeting, 2005)

  1. Gordon K. Lam, Adrianne Woods, Laura K. Hummers, Fredrick M. Wigley. Efficacy and safety of etanercept in scleroderma (SSc) ioint disease.
  2. Allan C. Gelber, Laura K. Hummers, Nae Y. Wang, Fredrick M. Wigley. Race and independent association with disease subtype, organ system involvement and serologic status in scleroderma.
  3. Kwas Huston, Livia Casciola-Rosen, Laura Hummers, Fred Wigley, Robert Wise, Antony Rosen. Fibrillin-1 predicts alveolitis in patients with scleroderma.
  4. Keary A. Cope, Steven F. Solga, Laura K. Hummers, Fredrick M. Wigley, Anna Mae Diehl, Terence H. Risby. Abnormal breath ethane concentrations in patients with systemic sclerosis.
  5. Laura K. Hummers, Fredrick M. Wigley. Scleromyxedema: a case series describing clinical features and long-term management with IVIG.